StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

Analysts at StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a report released on Thursday. The brokerage set a “sell” rating on the stock.

Bio-Path Stock Down 15.6 %

BPTH stock opened at $1.14 on Thursday. The business has a 50 day moving average of $0.89 and a 200-day moving average of $1.25. Bio-Path has a 12-month low of $0.59 and a 12-month high of $12.00.

Institutional Investors Weigh In On Bio-Path

An institutional investor recently bought a new stake in Bio-Path stock. Armistice Capital LLC acquired a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path as of its most recent filing with the Securities and Exchange Commission (SEC). 5.74% of the stock is currently owned by institutional investors.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.